PE20000265A1 - Composiciones que contienen virus y metodos para concentrar preparados de virus - Google Patents
Composiciones que contienen virus y metodos para concentrar preparados de virusInfo
- Publication number
- PE20000265A1 PE20000265A1 PE1999000137A PE00013799A PE20000265A1 PE 20000265 A1 PE20000265 A1 PE 20000265A1 PE 1999000137 A PE1999000137 A PE 1999000137A PE 00013799 A PE00013799 A PE 00013799A PE 20000265 A1 PE20000265 A1 PE 20000265A1
- Authority
- PE
- Peru
- Prior art keywords
- virus
- refers
- concentration
- preparation
- polyhydroxyhydrocarbon
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 10
- 238000002360 preparation method Methods 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 241000701161 unidentified adenovirus Species 0.000 abstract 2
- 239000004215 Carbon black (E152) Substances 0.000 abstract 1
- 238000013019 agitation Methods 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000012141 concentrate Substances 0.000 abstract 1
- 238000009295 crossflow filtration Methods 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 abstract 1
- 229930195733 hydrocarbon Natural products 0.000 abstract 1
- 150000002430 hydrocarbons Chemical class 0.000 abstract 1
- 229910052751 metal Inorganic materials 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 238000001471 micro-filtration Methods 0.000 abstract 1
- 238000003825 pressing Methods 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 230000000717 retained effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910000162 sodium phosphate Inorganic materials 0.000 abstract 1
- 239000001488 sodium phosphate Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 abstract 1
- 238000000108 ultra-filtration Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UNA COMPOSICION QUE COMPRENDE a)UN VIRUS TAL COMO UN VIRUS RECOMBINANTE (GEN p53 DEL TIPO NO CULTIVADO, ADENOVIRUS CON p53 TIPO NO CULTIVADO COMO UN TRANSGEN ACN53), ADENOVIRUS EN UNA CONCENTRACION DE 1*10(9) A 1*10(13) PARTICULAS/ml; b)UN POLIHIDROXI HIDROCARBURO TAL COMO GLICERINA, c)UN DISACARIDO (SACAROSA); d)UN TAMPON QUE COMPRENDE 0,5 mg/ml A 10 mg/ml DE FOSFATO DE SODIO MONOBASICO DIHIDRATADO Y DE 0,5 mg/ml A 10 mg/ml DE TROMETRAMINA QUE REGULA EL pH DE 7 A 8,5 A UNA TEMPERATURA DE 2°C - 27°C; e)DE 0,1 mg/ml A 1 mg/ml DE UNA SAL DE METAL DIVALENTE; f)UN DILUYENTE (AGUA). TAMBIEN SE REFIERE A UN METODO PARA CONCENTRAR UN PREPARADO DE VIRUS QUE COMPRENDE a)ADICIONAR UN POLIHIDROXI HIDROCARBURO A UN PREPARADO DE VIRUS HASTA UNA CONCENTRACION FINAL DE POLIHIDROXIHIDROCARBURO DE 20%; b)SOMETER EL PREPARADO A UN PROCESO DE FILTRACION (ULTRAFILTRACION, FILTRACION DE FLUJO TANGENCIAL) EN EL CUAL LA CONCENTRACION DE VIRUS SE INCREMENTA APLICANDO PRESION AL PREPARADO DE VIRUS A TRAVES DE UN FILTRO MIENTRAS, EL VIRUS ES RETENIDO; c)SOMETER A UNA ETAPA DE AGITACION SEGUIDA DE MICROFILTRACION EVITANDO LA FORMACION DE PARTICULAS DURANTE EL ALMACENAMIENTO. TAMBIEN SE REFIERE A UN METODO DE PURIFICACION. LA COMPOSICION PUEDE SER UTIL PARA MANTENER LA ESTABILIDAD DE LOS VIRUS QUE SE UTILIZAN EN TERAPIA GENETICA
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2446298A | 1998-02-17 | 1998-02-17 | |
| US7964398A | 1998-05-15 | 1998-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20000265A1 true PE20000265A1 (es) | 2000-04-25 |
Family
ID=26698472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1999000137A PE20000265A1 (es) | 1998-02-17 | 1999-02-16 | Composiciones que contienen virus y metodos para concentrar preparados de virus |
Country Status (25)
| Country | Link |
|---|---|
| EP (4) | EP1054955B1 (es) |
| JP (3) | JP4358434B2 (es) |
| KR (5) | KR100912362B1 (es) |
| CN (2) | CN100374551C (es) |
| AR (3) | AR020054A1 (es) |
| AT (3) | ATE478945T1 (es) |
| AU (1) | AU757976B2 (es) |
| BR (1) | BR9908015A (es) |
| CA (2) | CA2723040A1 (es) |
| CO (1) | CO4820440A1 (es) |
| DE (3) | DE69933433T2 (es) |
| DK (1) | DK1054955T3 (es) |
| ES (2) | ES2272053T3 (es) |
| HK (3) | HK1073481A1 (es) |
| HU (1) | HU226015B1 (es) |
| ID (1) | ID28298A (es) |
| IL (2) | IL137510A0 (es) |
| MY (1) | MY141641A (es) |
| NO (1) | NO20004104L (es) |
| PE (1) | PE20000265A1 (es) |
| PL (1) | PL197747B1 (es) |
| PT (1) | PT1054955E (es) |
| SK (1) | SK11842000A3 (es) |
| TW (1) | TWI232107B (es) |
| WO (1) | WO1999041416A2 (es) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100503701B1 (ko) | 1996-11-20 | 2005-07-26 | 인트로겐 테라페티스, 인코퍼레이티드 | 아데노바이러스 벡터를 생산하고 정제하는 개선된 방법 |
| US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| EP1133316B1 (en) * | 1998-11-16 | 2009-01-21 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| US6689600B1 (en) | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| AU4346101A (en) * | 2000-03-07 | 2001-09-17 | Merck & Co., Inc. | Adenovirus formulations |
| US7456009B2 (en) | 2000-03-07 | 2008-11-25 | Merck & Co., Inc. | Adenovirus formulations |
| US20020064860A1 (en) | 2000-11-29 | 2002-05-30 | Schering Corporation | Method for purifying adenoviruses |
| WO2002047726A2 (en) * | 2000-12-12 | 2002-06-20 | Japan Tobacco Inc. | Pharmaceutical composition containing an active with a hemolytic action and a surfactant |
| EP1453536A4 (en) | 2001-12-12 | 2009-08-26 | Mayne Pharma Int Pty Ltd | COMPOSITION FOR PRESERVING VIRUSES |
| US20030153065A1 (en) * | 2002-01-14 | 2003-08-14 | Genvec, Inc. | Composition and method for maintaining non-enveloped viral vectors |
| US20030232018A1 (en) * | 2002-01-18 | 2003-12-18 | Berlex Biosciences | Stabilized formulations of adenovirus |
| AU2005214090B2 (en) | 2004-02-23 | 2008-09-11 | Crucell Holland B.V. | Virus purification methods |
| CA2586107A1 (en) | 2004-11-03 | 2006-05-18 | Introgen Therapeutics Inc. | A novel method for the production and purification of adenoviral vectors |
| JP4621743B2 (ja) | 2004-12-13 | 2011-01-26 | カンジ，インコーポレイテッド | 複製欠損アデノウイルスの産生のための細胞株 |
| CN101155915B (zh) | 2005-04-11 | 2013-12-04 | 克鲁塞尔荷兰公司 | 利用超滤进行病毒纯化 |
| CN1961961B (zh) * | 2005-11-11 | 2010-05-26 | 深圳市源兴生物医药科技有限公司 | 一种药物制剂及其制备方法 |
| JP5097714B2 (ja) | 2005-12-12 | 2012-12-12 | カンジ，インコーポレイテッド | Ｅ１領域内の発現カセットと不活性化されたｅ２ｂポリメラーゼを有するアデノウイルス発現ベクター |
| AU2007240797B2 (en) * | 2006-04-20 | 2013-05-23 | Wyeth Llc | Purification processes for isolating purified vesicular stomatitis virus from cell culture |
| ES2532015T3 (es) | 2008-11-03 | 2015-03-23 | Crucell Holland B.V. | Método para la producción de vectores adenovíricos |
| JP5879256B2 (ja) | 2009-05-02 | 2016-03-08 | ジェンザイム・コーポレーション | 神経変性障害のための遺伝子治療 |
| WO2011098592A1 (en) | 2010-02-15 | 2011-08-18 | Crucell Holland B.V. | Method for the production of ad26 adenoviral vectors |
| US8771709B2 (en) | 2010-09-20 | 2014-07-08 | Crucell Holland B.V. | Therapeutic vaccination against active Tuberculosis |
| US9168292B2 (en) | 2010-09-27 | 2015-10-27 | Crucell Holland B.V. | Heterologous prime boost vaccination regimen against malaria |
| AU2011336410B2 (en) | 2010-12-02 | 2015-01-22 | Oncolytics Biotech Inc. | Lyophilized viral formulations |
| WO2012075379A2 (en) | 2010-12-02 | 2012-06-07 | Oncolytics Biotech Inc. | Liquid viral formulations |
| EA201391605A1 (ru) * | 2011-04-29 | 2014-02-28 | Онколитикс Байотек Инк. | Способы очистки вирусов с использованием гельпроникающей хроматографии |
| US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| CN104379733B (zh) | 2012-03-12 | 2016-01-20 | 克鲁塞尔荷兰公司 | 具改变末端的重组腺病毒群 |
| US9125870B2 (en) | 2012-03-22 | 2015-09-08 | Crucell Holland B.V. | Vaccine against RSV |
| MY169352A (en) | 2012-03-22 | 2019-03-25 | Janssen Vaccines & Prevention Bv | Vaccine against rsv |
| MX361774B (es) | 2013-04-25 | 2018-12-17 | Janssen Vaccines & Prevention Bv | Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados. |
| PE20160045A1 (es) | 2013-06-17 | 2016-02-18 | Crucell Holland Bv | Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados |
| KR20170004966A (ko) * | 2014-05-28 | 2017-01-11 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | 바이러스 감소 방법 |
| US10570417B2 (en) | 2015-04-14 | 2020-02-25 | Janssen Vaccines & Prevention B.V. | Recombinant adenovirus expressing two transgenes with a bidirectional promoter |
| JP6840718B2 (ja) | 2015-07-07 | 2021-03-10 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | 安定化された可溶性融合前ｒｓｖ ｆポリペプチド |
| WO2017005844A1 (en) | 2015-07-07 | 2017-01-12 | Janssen Vaccines & Prevention B.V. | Vaccine against rsv |
| AU2017248021B2 (en) | 2016-04-05 | 2021-08-12 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F proteins |
| BR112018070323A2 (pt) | 2016-04-05 | 2019-01-29 | Janssen Vaccines & Prevention Bv | vacina contra rsv |
| WO2017207480A1 (en) | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
| US11001858B2 (en) | 2016-06-20 | 2021-05-11 | Janssen Vaccines & Prevention B.V. | Potent and balanced bidirectional promoter |
| WO2018011196A1 (en) | 2016-07-14 | 2018-01-18 | Janssen Vaccines & Prevention B.V. | Hpv vaccines |
| WO2018210871A1 (en) | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
| EP3624844A1 (en) | 2017-05-17 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
| WO2019021305A1 (en) * | 2017-07-24 | 2019-01-31 | Ella Foundation | VACCINE AGAINST FOOT AND MOUTH DISEASE |
| EP3681533A1 (en) | 2017-09-15 | 2020-07-22 | Janssen Vaccines & Prevention B.V. | Method for the safe induction of immunity against rsv |
| CN114173827A (zh) * | 2019-06-28 | 2022-03-11 | 武田药品工业株式会社 | 腺相关病毒纯化方法 |
| JP2023512519A (ja) | 2020-01-31 | 2023-03-27 | ベス イスラエル ディーコネス メディカル センター インコーポレイテッド | コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン |
| WO2022175477A1 (en) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv fb antigens |
| WO2023020556A1 (zh) * | 2021-08-17 | 2023-02-23 | 上海行深生物科技有限公司 | 病毒制剂、用于配制病毒制剂的溶液及其用途 |
| WO2023020939A1 (en) | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023111725A1 (en) | 2021-12-14 | 2023-06-22 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE299213C (es) * | ||||
| US4147772A (en) * | 1976-02-03 | 1979-04-03 | Merck & Co., Inc. | Vaccine stabilizer |
| GB1575155A (en) * | 1978-04-11 | 1980-09-17 | Merck & Co Inc | Vaccine stabilizer |
| BE866330A (fr) * | 1978-04-25 | 1978-10-25 | Merck & Co Inc | Procede de fabrication d'un agent de stabilisation de vaccin |
| US5532220A (en) | 1987-08-31 | 1996-07-02 | The Regents Of The University Of California | Genetic mechanisms of tumor suppression |
| DD299213A7 (de) * | 1988-05-04 | 1992-04-09 | Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De | Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung |
| DD295927A5 (de) * | 1988-05-06 | 1991-11-14 | Saechsisches Serumwerk Gmbh Dresden, | Immobilisiertes immunologisch aktives reagens |
| DE69434594T2 (de) | 1993-10-25 | 2006-09-21 | Canji, Inc., San Diego | Rekombinante adenoviren-vektor und verfahren zur verwendung |
| KR100368686B1 (ko) * | 1994-12-29 | 2003-12-01 | 주식회사 엘지생명과학 | 수크로즈를이용한세포와바이러스의분리방법 |
| FR2742756B1 (fr) * | 1995-12-22 | 1998-04-03 | Pasteur Merieux Serums Vacc | Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation |
| US5789244A (en) | 1996-01-08 | 1998-08-04 | Canji, Inc. | Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems |
-
1999
- 1999-02-12 BR BR9908015-0A patent/BR9908015A/pt not_active Application Discontinuation
- 1999-02-12 ES ES99906690T patent/ES2272053T3/es not_active Expired - Lifetime
- 1999-02-12 JP JP2000531596A patent/JP4358434B2/ja not_active Expired - Fee Related
- 1999-02-12 DE DE69933433T patent/DE69933433T2/de not_active Expired - Lifetime
- 1999-02-12 EP EP99906690A patent/EP1054955B1/en not_active Expired - Lifetime
- 1999-02-12 ES ES04030395T patent/ES2290613T3/es not_active Expired - Lifetime
- 1999-02-12 DE DE69942708T patent/DE69942708D1/de not_active Expired - Lifetime
- 1999-02-12 EP EP04030394A patent/EP1526173B1/en not_active Expired - Lifetime
- 1999-02-12 AT AT06019642T patent/ATE478945T1/de not_active IP Right Cessation
- 1999-02-12 KR KR1020087008928A patent/KR100912362B1/ko not_active IP Right Cessation
- 1999-02-12 DK DK99906690T patent/DK1054955T3/da active
- 1999-02-12 AT AT04030395T patent/ATE371020T1/de not_active IP Right Cessation
- 1999-02-12 EP EP04030395A patent/EP1526174B1/en not_active Expired - Lifetime
- 1999-02-12 ID IDW20001574A patent/ID28298A/id unknown
- 1999-02-12 CA CA2723040A patent/CA2723040A1/en not_active Abandoned
- 1999-02-12 SK SK1184-2000A patent/SK11842000A3/sk unknown
- 1999-02-12 CA CA2320419A patent/CA2320419C/en not_active Expired - Fee Related
- 1999-02-12 TW TW088102219A patent/TWI232107B/zh not_active IP Right Cessation
- 1999-02-12 KR KR1020097022935A patent/KR101018992B1/ko not_active IP Right Cessation
- 1999-02-12 AT AT99906690T patent/ATE341614T1/de not_active IP Right Cessation
- 1999-02-12 WO PCT/US1999/001873 patent/WO1999041416A2/en active IP Right Grant
- 1999-02-12 CN CNB998050989A patent/CN100374551C/zh not_active Expired - Fee Related
- 1999-02-12 AU AU26538/99A patent/AU757976B2/en not_active Ceased
- 1999-02-12 PT PT99906690T patent/PT1054955E/pt unknown
- 1999-02-12 CN CN2007101670867A patent/CN101164623B/zh not_active Expired - Fee Related
- 1999-02-12 KR KR1020087008929A patent/KR100918187B1/ko not_active IP Right Cessation
- 1999-02-12 KR KR1020097004676A patent/KR100991683B1/ko not_active IP Right Cessation
- 1999-02-12 KR KR1020007008878A patent/KR100862169B1/ko not_active IP Right Cessation
- 1999-02-12 HU HU0100670A patent/HU226015B1/hu not_active IP Right Cessation
- 1999-02-12 PL PL342847A patent/PL197747B1/pl not_active IP Right Cessation
- 1999-02-12 IL IL13751099A patent/IL137510A0/xx unknown
- 1999-02-12 DE DE69936948T patent/DE69936948T2/de not_active Expired - Lifetime
- 1999-02-12 EP EP06019642A patent/EP1741777B1/en not_active Expired - Lifetime
- 1999-02-15 MY MYPI99000542A patent/MY141641A/en unknown
- 1999-02-16 CO CO99009282A patent/CO4820440A1/es unknown
- 1999-02-16 PE PE1999000137A patent/PE20000265A1/es not_active Application Discontinuation
- 1999-02-23 AR ARP990100656A patent/AR020054A1/es active IP Right Grant
-
2000
- 2000-07-25 IL IL137510A patent/IL137510A/en not_active IP Right Cessation
- 2000-08-16 NO NO20004104A patent/NO20004104L/no not_active Application Discontinuation
- 2000-12-01 HK HK05106734A patent/HK1073481A1/xx not_active IP Right Cessation
- 2000-12-01 HK HK00107727A patent/HK1028416A1/xx not_active IP Right Cessation
-
2006
- 2006-02-07 JP JP2006030336A patent/JP2006166925A/ja not_active Withdrawn
-
2007
- 2007-05-10 HK HK07104995.0A patent/HK1097413A1/xx not_active IP Right Cessation
- 2007-10-16 AR ARP070104576A patent/AR063314A2/es unknown
- 2007-10-16 AR ARP070104577A patent/AR063315A2/es unknown
-
2010
- 2010-07-08 JP JP2010156257A patent/JP2010213727A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20000265A1 (es) | Composiciones que contienen virus y metodos para concentrar preparados de virus | |
| Spelsberg et al. | Proteins of chromatin in template restriction: III. The macromolecules in specific restriction of the chromatin DNA | |
| ES2306450T3 (es) | Procedimientos nuevos de purificacion del factor ix. | |
| AR241596A1 (es) | Un metodo para extraer y purificar hbsag fijada a celulas a partir del sobrenadante de celulas de levadura producidas artificialmente. | |
| JP2002503484A5 (es) | ||
| JPS5944322A (ja) | 抗血友病性因子濃厚物の調製法 | |
| JP2644946B2 (ja) | ＩｇＧ− モノクロナール抗体の精製方法及びその使用方法 | |
| CA2736104A1 (en) | A method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition | |
| NO324659B1 (no) | Utvinning av von Willebrand-faktor ved kationebytterkromatografi samt preparat inneholdende slik faktor og anvendelse derav. | |
| ES2770860T3 (es) | Métodos de purificación y/o inactivación viral | |
| JPS6217994B2 (es) | ||
| DK1103618T3 (da) | Fremgangsmåde til oprensning af 1,3-propandiol fra fermenteringsmedie | |
| JPS6042207B2 (ja) | 胎盤よりプラスミノ−ゲン型活性化合物を抽出する方法 | |
| ES2224094T3 (es) | Procedimiento para preparar seroalbumina normal (humana) esencialmente monomerica. | |
| ES2543829T3 (es) | Procedimiento para la preparación del inhibidor de proteinasa alfa-1 | |
| JPS57203017A (en) | Purifying method of immunoglobulin | |
| Zeppezauera et al. | A 81Br nuclear magnetic resonance study of bromide ion binding to proteins in aqueous solution | |
| JPH04506349A (ja) | タンパク質の浄化方法 | |
| ES2203618T3 (es) | Procedimiento de purificacion de una solucion acuosa de albumina bruta. | |
| DK1465687T3 (da) | Fremstilling af dialysekoncentrat fra et höjfortættet koncentratforstadium og indretning til anvendelse på dialysestedet | |
| Carroll et al. | Alanine uptake by isolated zooxanthellae of the mangrove jellyfish, Cassiopea xamachana. II. Inhibition by host homogenate fraction | |
| SE7906137L (sv) | Rening av faktor viii | |
| Williamson | Purification of DNA by isopycnic banding in cesium chloride in a zonal rotor | |
| JP2005245269A (ja) | 血清アルブミン多量体を含む遺伝子組換え型蛋白質 | |
| Idriss et al. | Studies on cytosolic guanylate cyclase from human placenta |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |